KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Amgen has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $2.46 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $2.46 for Q4 2025, up 112.07% from a year ago — trailing twelve months through Dec 2025 was $14.24 (up 88.61% YoY), and the annual figure for FY2025 was $14.23, up 88.23%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $2.46 at Amgen, down from $5.93 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for AMGN hit a ceiling of $5.93 in Q3 2025 and a floor of -$0.21 in Q1 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $2.76 (2022), compared with a mean of $2.84.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 103.98% in 2024 and later surged 1623.81% in 2025.
  • Amgen's EPS (Weighted Average and Diluted) stood at $3.35 in 2021, then fell by 10.45% to $3.0 in 2022, then crashed by 52.33% to $1.43 in 2023, then decreased by 18.88% to $1.16 in 2024, then soared by 112.07% to $2.46 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $2.46 (Q4 2025), $5.93 (Q3 2025), and $2.65 (Q2 2025) per Business Quant data.